9L PROBE
Device
GE HEALTHCARE
Total Payments
$32,301
Transactions
2
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $32,301 | 2 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $32,301 | 2 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| UTILIZING CAROTID FLOW TIME AND VOLUME TO DETERMINE FLUID RESPONSIVENESS AND PREDICT CLINICAL OUTCOME OF PATIENTS WITH SEPTIC SHOCK | GE HEALTHCARE | $22,930 | 0 |
| VERY EARLY IDENTIFICATION OF SHOCK BY ULTRASOUND EXAM (VENUE) EMERGENCY DEPARTMENT STUDY | GE HEALTHCARE | $9,371 | 0 |
Top Doctors Receiving Payments for 9L PROBE
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Boston, MA | $32,301 | 2 |
Ad
Manufacturing Companies
- GE HEALTHCARE $32,301
Product Information
- Type Device
- Total Payments $32,301
- Total Doctors 0
- Transactions 2
About 9L PROBE
9L PROBE is a device associated with $32,301 in payments to 0 healthcare providers, recorded across 2 transactions in the CMS Open Payments database. The primary manufacturer is GE HEALTHCARE.
Payment data is available from 2018 to 2018. In 2018, $32,301 was paid across 2 transactions to 0 doctors.
The most common payment nature for 9L PROBE is "Unspecified" ($32,301, 100.0% of total).
9L PROBE is associated with 2 research studies, including "UTILIZING CAROTID FLOW TIME AND VOLUME TO DETERMINE FLUID RESPONSIVENESS AND PREDICT CLINICAL OUTCOME OF PATIENTS WITH SEPTIC SHOCK" ($22,930).